| dbo:abstract |
بي أف-219,061 (بالإنجليزية: PF-219,061) هي مادة تطورها فايزر ذات تأثير قوي وانتقائي تجاه . تجرى عليها الأبحاث لاحتمال فعاليتها في علاج . (ar) PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials. (en) |
| dbo:casNumber |
710654-74-3 |
| dbo:fdaUniiCode |
ZK5ZP8L5S2 |
| dbo:pubchem |
9794475 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/PF-219,061_Structural_Formulae.png?width=300 |
| dbo:wikiPageID |
24380895 (xsd:integer) |
| dbo:wikiPageLength |
4270 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1058926788 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cabergoline dbr:Pramipexole dbr:Bremelanotide dbr:Pfizer dbc:Abandoned_drugs dbc:Pfizer_brands dbc:Phenols dbr:Melanotan_II dbr:Functional_selectivity dbc:Aphrodisiacs dbr:Tibolone dbr:UK-414,495 dbr:ABT-670 dbr:ABT-724 dbr:Agonist dbr:Drug_development dbr:Flibanserin dbc:Female_sexual_dysfunction_drugs dbr:PF-592,379 dbr:Female_sexual_dysfunction dbr:Receptor_(biochemistry) dbc:Dopamine_agonists dbc:Phenylmorpholines dbr:Dopamine dbr:D3_receptor dbr:OSU-6162 dbr:Intrinsa |
| dbp:c |
13 (xsd:integer) |
| dbp:casNumber |
710654 (xsd:integer) |
| dbp:chemspiderid |
7970242 (xsd:integer) |
| dbp:h |
19 (xsd:integer) |
| dbp:iupacName |
-3 (xsd:integer) |
| dbp:legalStatus |
Investigational (en) |
| dbp:n |
1 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
9794475 (xsd:integer) |
| dbp:routesOfAdministration |
Nasal (en) |
| dbp:smiles |
CCCN1CCO[C@@H]C2=CCO (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
WYEGTIGJSHGEID-ZDUSSCGKSA-N (en) |
| dbp:unii |
ZK5ZP8L5S2 (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
451228063 (xsd:integer) |
| dbp:width |
200 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Dopaminergics dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Stdinchicite |
| dcterms:subject |
dbc:Abandoned_drugs dbc:Pfizer_brands dbc:Phenols dbc:Aphrodisiacs dbc:Female_sexual_dysfunction_drugs dbc:Dopamine_agonists dbc:Phenylmorpholines |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAphrodisiacs yago:Agent114778436 yago:Aphrodisiac102727281 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Stimulant104320126 yago:Substance100020090 yago:WikicatFemaleSexualDysfunctionDrugs umbel-rc:DrugProduct |
| rdfs:comment |
بي أف-219,061 (بالإنجليزية: PF-219,061) هي مادة تطورها فايزر ذات تأثير قوي وانتقائي تجاه . تجرى عليها الأبحاث لاحتمال فعاليتها في علاج . (ar) PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials. (en) |
| rdfs:label |
بي أف-219061 (ar) PF-219,061 (en) |
| owl:sameAs |
freebase:PF-219,061 yago-res:PF-219,061 wikidata:PF-219,061 dbpedia-ar:PF-219,061 dbpedia-sh:PF-219,061 dbpedia-sr:PF-219,061 https://global.dbpedia.org/id/4scr9 |
| prov:wasDerivedFrom |
wikipedia-en:PF-219,061?oldid=1058926788&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/PF-219,061_Structural_Formulae.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:PF-219,061 |
| is dbo:wikiPageWikiLink of |
dbr:List_of_dopaminergic_drugs dbr:C13H19NO2 dbr:Dopamine_receptor_D3 dbr:UK-414,495 dbr:3-PPP dbr:ABT-670 dbr:ABT-724 dbr:PD-128,907 dbr:PF-00446687 dbr:PF-592,379 dbr:OSU-6162 dbr:Substituted_phenylmorpholine |
| is foaf:primaryTopic of |
wikipedia-en:PF-219,061 |
